FDA Approves Sanofi's Infilbray as First Treatment for Neurological Symptoms of Type 3 Gaucher Disease

The once-daily pill reaches the brain, where enzyme therapy cannot, opening treatment for progressive cognitive and coordination symptoms.

Sources

Sources & evidence

What “Source checked” means

SNYLatest quote

The FDA approved Sanofi's Infilbray on Wednesday, the first treatment for the neurological symptoms of Type 3 Gaucher disease.

The U.S. Food and Drug Administration approved Infilbray (venglustat) tablets on Wednesday, November 18, 2026. The approval was granted to Genzyme Corporation, a Sanofi company.

The drug is approved for adults and pediatric patients weighing at least 15 kilograms, about 33 pounds. Sanofi is listed on Euronext as SAN and on Nasdaq as SNY.

Acting FDA Commissioner Kyle Diamantas said the drug can “get to the source of the buildup driving the neurological symptoms.” He tied the approval to the agency's commitment to rare diseases.

A drug built to reach the brain

Infilbray is an oral glucosylceramide synthase inhibitor, a drug that slows production of fatty substances. It is taken once daily and crosses the blood-brain barrier.

Type 3 Gaucher disease, or GD3, is a rare inherited lysosomal storage disorder. A deficient or malfunctioning enzyme, glucocerebrosidase, lets glucosphingolipids build up in organs and the brain.

GD3 is the chronic neuronopathic form, the form that involves the nervous system. Its brain symptoms include cognitive deficits, ataxia and problems with speech, memory and thinking.

Those symptoms worsen progressively over time. Until now, no approved treatment targeted the neurological manifestations themselves.

Sanofi already sells Cerdelga for type 1 disease, according to Reuters. It also sells Cerezyme for symptoms outside the brain in types 1 and 3, Reuters reported.

The trial behind the approval

The approval rests on LEAP2MONO, a phase 3 study registered as NCT05222906. It enrolled 43 patients aged 12 years and older with GD3 neurological manifestations.

Every patient had first stabilized systemic manifestations on enzyme replacement therapy. Sanofi says participants had received that therapy for at least three years and met therapeutic goals.

The study was randomized, double-blind and double-dummy, with an active comparator. Patients took oral Infilbray once daily or intravenous imiglucerase every two weeks for 52 weeks.

The primary endpoint combined two measures tracked from baseline to Week 52. One was the modified SARA score, a four-item motor and ataxia scale.

The other was the RBANS total scale index, a measure of cognition. A prespecified global test, the O'Brien ordinary least squares test, combined the endpoints.

Infilbray showed statistically significant superiority on that global test, with p=0.0137. The FDA describes the result as improvement on a measure combining both assessments versus enzyme therapy.

No effect sizes beyond that p-value were published in either primary source. The open-label phase of the study is still ongoing, Sanofi said.

Safety warnings travel with the approval

Infilbray carries warnings for suicidal ideation and behavior. It also carries warnings for lens opacification in pediatric patients and embryofoetal toxicity.

In the primary analysis period, diarrhea was reported in 14% of Infilbray patients and none on imiglucerase. Splenomegaly was also 14% against none, and nausea 14% against 5%.

Depression was reported in 10% against none, and gastroenteritis in 10% against none. Vomiting was 10% against 5%.

The groups were small: 21 patients received Infilbray and 22 received imiglucerase. The FDA says the most frequent side effects were gastrointestinal symptoms and mood effects.

Dr. Pramod Mistry of Yale said neurological manifestations had remained beyond the reach of available therapies. He called a medicine able to address them a major milestone.

What remains unknown

What remains unknown starts with price and launch timing. Neither the FDA nor Sanofi disclosed either in the approval materials.

How large the benefit is in everyday terms is also unknown. The primaries publish the combined test result, not separate effect sizes.

Longer-term outcomes are unknown as well. The open-label phase is ongoing, and its results will be presented later.

The tests that come next

The first test is regulatory. Infilbray is under review for GD3 in the European Union, Japan and other jurisdictions.

Sanofi plans further global submissions in 2026 and 2027. Decisions there will show how far the U.S. approval travels.

The second test is the open-label data. Whether the neurological gains hold beyond 52 weeks remains to be shown.

The drug previously earned Orphan Drug designation and Priority Review from the FDA. Sanofi adds breakthrough therapy, rare pediatric disease and fast-track designations in the U.S.

Sources & evidence

Source checked3 sources · 7 figures

Figure receipts

Every figure in this article, with the source it came from.

  • 43 LEAP2MONO phase 3 enrollment

    As of Nov. 18, 2026

  • 15 Infilbray minimum patient weight for the approved indication

    As of Nov. 18, 2026

  • 0.0137 LEAP2MONO global test of multiple neurological endpoints, p-value

    As of Nov. 18, 2026

  • 52 LEAP2MONO treatment duration

    As of Nov. 18, 2026

  • 14 LEAP2MONO diarrhea adverse reaction rate, Infilbray arm

    As of Nov. 18, 2026

  • 21 LEAP2MONO Infilbray arm size

    As of Nov. 18, 2026

  • 22 LEAP2MONO imiglucerase arm size

    As of Nov. 18, 2026

As of Wednesday, Nov. 18, 2026.

TickerGrove house illustration for healthcare coverage: a double helix

Get the Morning Brief — Weekday Morning Brief · Saturday Weekend Brief · Sunday Week Ahead

Discuss this story. Join TickerGrove on Discord to talk companies, earnings, and markets, or request future coverage.

Disclaimer

TickerGrove is education and journalism only. It is not investment advice, not a broker-dealer, and not a recommendation to buy, sell, or hold any security.

Nothing on this site is a pick or a return promise. Official economic prints and company filings are dated observations. External quote links open a separate service; TickerGrove does not host those prices.

Companies · All stories